Cardiovascular Toxicities of Androgen Deprivation Therapy.
Androstenes
/ therapeutic use
Antineoplastic Agents, Hormonal
/ adverse effects
COVID-19
/ epidemiology
Cardiotoxicity
Cardiovascular Diseases
/ chemically induced
Disease Susceptibility
Gonadotropin-Releasing Hormone
/ agonists
Health Status Disparities
Humans
Male
Prostatic Neoplasms
/ drug therapy
SARS-CoV-2
Cardiotoxicity
Cardiovascular disease
Hormones
Mortality
Prevention
Prostate cancer
Side effects
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
17 04 2021
17 04 2021
Historique:
accepted:
16
03
2021
entrez:
18
4
2021
pubmed:
19
4
2021
medline:
5
5
2021
Statut:
epublish
Résumé
Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.
Identifiants
pubmed: 33866442
doi: 10.1007/s11864-021-00846-z
pii: 10.1007/s11864-021-00846-z
pmc: PMC8053026
doi:
Substances chimiques
Androstenes
0
Antineoplastic Agents, Hormonal
0
Gonadotropin-Releasing Hormone
33515-09-2
abiraterone
G819A456D0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL126949
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
J Am Acad Dermatol. 2020 Aug;83(2):680-682
pubmed: 32446821
J Clin Endocrinol Metab. 2016 Jul;101(7):2776-84
pubmed: 27167057
Drug Des Devel Ther. 2012;6:13-8
pubmed: 22291466
Rev Urol. 2001;3 Suppl 3:S10-4
pubmed: 16986003
Curr Oncol Rep. 2020 Jul 23;22(9):96
pubmed: 32700096
Cancer. 2007 Oct 1;110(7):1493-500
pubmed: 17657815
J Am Acad Dermatol. 2020 Nov;83(5):e353-e354
pubmed: 32707256
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Urology. 2008 Jun;71(6):1001-6
pubmed: 18407326
Cancer. 2013 May 15;119(10):1808-15
pubmed: 23400678
Circulation. 2018 Jul 3;138(1):110-113
pubmed: 29967236
Clin Endocrinol (Oxf). 2002 Aug;57(2):209-14
pubmed: 12153599
JAMA. 2011 Dec 7;306(21):2359-66
pubmed: 22147380
Br J Cancer. 2017 Oct 10;117(8):1233-1240
pubmed: 29017178
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Hormones (Athens). 2017 Apr;16(2):115-123
pubmed: 28742500
Urol Oncol. 2014 Nov;32(8):1126-34
pubmed: 25242517
J Clin Oncol. 2007 Jun 10;25(17):2420-5
pubmed: 17557956
Am J Med. 1998 Jul 6;105(1A):32S-39S
pubmed: 9707266
Eur Urol. 2021 Jan;79(1):44-53
pubmed: 32605859
J Clin Oncol. 2010 Jul 20;28(21):3448-56
pubmed: 20567006
J Urol. 2020 Jun;203(6):1109-1116
pubmed: 31899651
J Androl. 2009 Jul-Aug;30(4):410-5
pubmed: 19168445
J Endocrinol. 2012 Apr;213(1):77-87
pubmed: 22281525
Aging Cell. 2015 Jun;14(3):409-20
pubmed: 25754247
Circulation. 2019 Sep 24;140(13):1070-1080
pubmed: 31378084
Ann Oncol. 2020 Oct;31(10):1415-1416
pubmed: 32562741
J Cosmet Dermatol. 2020 Jul;19(7):1545-1547
pubmed: 32301221
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
pubmed: 17925537
Clin Exp Immunol. 2005 Oct;142(1):103-10
pubmed: 16178862
N Engl J Med. 2013 Apr 11;368(15):1458-9
pubmed: 23574133
Urologe A. 2016 Feb;55(2):218-25
pubmed: 26637324
J Urol. 2014 Jan;191(1):60-7
pubmed: 23770146
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46
pubmed: 19996060
J Clin Oncol. 2009 Jul 20;27(21):3452-8
pubmed: 19506162
Ann Oncol. 2020 Aug;31(8):1040-1045
pubmed: 32387456
J Oncol. 2015;2015:820403
pubmed: 26300918
J Urol. 2002 Apr;167(4):1670-4
pubmed: 11912385
Cancer Prev Res (Phila). 2019 Sep;12(9):585-598
pubmed: 31266828
J Endocrinol. 2003 Sep;178(3):373-80
pubmed: 12967330
Urology. 2001 Nov;58(5):756-61
pubmed: 11711355
Ther Clin Risk Manag. 2020 May 07;16:393-401
pubmed: 32440137
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1411-6
pubmed: 21708431
Cancer. 2021 May 1;127(9):1517-1528
pubmed: 32895938
Eur Urol. 2014 Jan;65(1):177-85
pubmed: 22981136
Eur Urol. 2015 Sep;68(3):386-96
pubmed: 25484142
J Mol Endocrinol. 2015 Feb;54(1):R15-29
pubmed: 25351819
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13
pubmed: 19887582
Circulation. 2016 Feb 2;133(5):537-41
pubmed: 26831435
N Engl J Med. 2020 Jun 4;382(23):2187-2196
pubmed: 32469183
N Engl J Med. 2014 Oct 30;371(18):1755-6
pubmed: 25354111
J Geriatr Cardiol. 2016 Feb;13(2):183-96
pubmed: 27168746
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
J Urol. 2001 May;165(5):1585-9
pubmed: 11342922
J Oncol Pract. 2018 Oct;14(10):580-587
pubmed: 30312560
Ann Oncol. 2012 Jul;23(7):1665-71
pubmed: 22228452
J Clin Oncol. 2007 Apr 20;25(12):1596-605
pubmed: 17404365
Arch Cardiovasc Dis. 2020 Jan;113(1):9-21
pubmed: 31685432
J Clin Oncol. 2011 Sep 10;29(26):3510-6
pubmed: 21844498
BJU Int. 2008 Dec;102(11):1531-8
pubmed: 19035858
Medicine (Baltimore). 2016 Jul;95(27):e3845
pubmed: 27399062
Am J Clin Exp Urol. 2017 Nov 09;5(3):34-48
pubmed: 29181436
Urol Res. 1992;20(5):317-21
pubmed: 1455564
JAMA Oncol. 2019 Oct 01;5(10):e191870
pubmed: 31415071
Clin Genitourin Cancer. 2019 Oct;17(5):e871-e877
pubmed: 31378578
FEBS Lett. 2002 Oct 23;530(1-3):129-32
pubmed: 12387879
N Engl J Med. 2010 Nov 4;363(19):1822-32
pubmed: 21047226
Ann Oncol. 2020 Oct;31(10):1419-1420
pubmed: 32653425
J Natl Compr Canc Netw. 2020 Nov 3;:1-10
pubmed: 33142266
Prostate. 2020 May;80(6):527-544
pubmed: 32130741
Cancer. 2016 Dec 1;122(23):3608-3614
pubmed: 27490845
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
pubmed: 16514137
Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):676-680
pubmed: 31915143
Eur Urol. 2014 Mar;65(3):565-73
pubmed: 24210090
Urology. 2003 Feb;61(2 Suppl 1):14-24
pubmed: 12667883
Thromb Res. 2007;121(1):127-34
pubmed: 17451792
J Urol. 2015 Apr;193(4):1226-31
pubmed: 25451829
Circulation. 2010 Feb 16;121(6):833-40
pubmed: 20124128
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1238-60
pubmed: 26921821
Theranostics. 2017 Oct 17;7(19):4671-4688
pubmed: 29187895
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Natl Cancer Inst. 2012 Sep 5;104(17):1335-42
pubmed: 22835388
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
pubmed: 11836291
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
J Clin Endocrinol Metab. 1999 Feb;84(2):743-50
pubmed: 10022447
Endocrinology. 2010 Nov;151(11):5428-37
pubmed: 20861231
J Clin Endocrinol Metab. 2017 May 1;102(5):1478-1485
pubmed: 27992261
J Urol. 2019 Dec;202(6):1199-1208
pubmed: 31188734
Am J Public Health. 2010 Apr;100(4):693-701
pubmed: 19608952
Biol Reprod. 2003 Jun;68(6):2215-21
pubmed: 12606332
J Clin Oncol. 2013 Aug 20;31(24):2991-7
pubmed: 23775960
Clin Genitourin Cancer. 2018 Jun;16(3):e645-e653
pubmed: 29339044
PLoS One. 2014 Sep 29;9(9):e107516
pubmed: 25264674
J Clin Oncol. 2015 Apr 10;33(11):1243-51
pubmed: 25732167
World J Urol. 2013 Apr;31(2):289-92
pubmed: 22898989
BJU Int. 2015 Sep;116(3):358-65
pubmed: 25124891